- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00886795
Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy (TAHOE)
December 17, 2015 updated by: Clifton O Bingham, Johns Hopkins University
A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy.
This study is being done to find out if a drug called Abatacept (Orencia ®) is safe and effective in treating people with chronic urticaria (persistent hives).
Study Overview
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins Arthritis Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Chronic active urticaria defined as symptoms > 50% of days or 3 days/week for more than 12 weeks
- Chronic therapy with stable doses of antihistamines for at least 4 weeks (patients may be taking more than one antihistamine or be taking combinations of antihistamines and leukotriene receptor antagonists) AND failure to respond to at least maximally approved dosages of 2 different antihistamine therapies
One of the following 3 conditions:
- Previous or ongoing requirement for corticosteroids for symptom control OR
- Prior steroid treatment with steroid discontinuation due to unacceptable morbidity
- Previous or current use (without symptom control or with unacceptable morbidity: e.g., hypertension from cyclosporine, hemolysis from dapsone) of immunomodulatory treatment for urticaria (e.g., hydroxychloroquine, methotrexate, sulfasalazine, dapsone, cyclosporine, intravenous immunoglobulin (IVIg), mycophenolate, azathioprine, etc)
- High baseline score for pruritis (at least 2 on a 3 point scale)
- No underlying etiology clearly defined for urticaria
Patients should exhibit evidence of underlying autoimmunity of at least one of the following:
- elevated erythrocyte sedimentation rate (ESR), C-Reactive Protein (CRP), anti-nuclear antibody (ANA)
- extractable nuclear antigens
- Thyroid antibodies
- other autoantibodies (e.g., intrinsic factor, parietal cell, ovarian), *elevated complement levels
- clinical characteristics suggestive of systemic autoimmune disease but without satisfying criteria for another diagnosis (e.g., arthralgias, myalgias, arthritis, low grade fever, significant fatigue associated with outbreaks)
- family history of autoimmune disease including thyroid autoimmunity
- a biopsy showing perivascular lymphocytic or mixed cellular infiltrate without vasculitis
- Concomitant use of hydroxychloroquine, methotrexate, or sulfasalazine will be permitted if dose stable for at least 8 weeks
- Concomitant use of steroids (≤ 15 mg/d Prednisone or equivalent) will be permitted if stable for 4 weeks and patient agrees to continue dose for the first 90 days
- Negative pregnancy test (for women of child-bearing age)
- Men and women of reproductive potential must agree to use an acceptable birth control during treatment and for 3 months after treatment
- No planned elective surgical procedures for at least 6 months from day#1
Exclusion Criteria:
- Current use of other immunosuppressive medications (cyclosporine, tacrolimus, sirolimus, IVIg, cyclophosphamide, mycophenolate mofetil, azathioprine). Any such medication will be discontinued for at least 4 weeks before study drug start.
- Concomitant treatment with corticosteroids (≤ 15 mg/d), hydroxychloroquine, methotrexate, and sulfasalazine will be permitted if doses are stable at least 8 weeks
- Treatment with an investigational agent within 4 weeks of screening or 5 half-lives of the investigational drug (whichever is longer)
- Receipt of a live vaccine within 4 weeks of randomization
- Prior treatment with Abatacept (Orencia®)
- Previous treatment with Rituximab (MabThera®/Rituxan®), unless 6 months after administration AND B cell reconstitution has occurred into normal range
- History of severe allergic or anaphylactic reactions to monoclonal antibodies or Fc fusion proteins
- History of significant laryngeal edema, tongue swelling, or airway compromise in the setting of urticarial/angioedema episode (isolated perioral, lip, and periorbital edema will not be exclusionary)
- Known history of Human Immunodeficiency Virus (HIV), Hepatitis B and/or Hepatitis C
- purified protein derivative (PPD) testing as part of screening that is positive*
- HIV, Hepatitis B surface antigen or Core Antibody positive, or anti Hepatitis C Antibody positive detected with screening
- History of recurrent significant infection, active bacterial, viral, fungal, mycobacterial, or other infection excluding fungal infections of nail beds, or major infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 wks of screening
- Known immunodeficiency, hypogammaglobulinemia, etc.
- Systemic lupus erythematosus (meeting American College of Rheumatology (ACR)) criteria; patients with autoantibodies such as ANA will NOT be excluded)
- Lack of peripheral venous access
- Drug, alcohol, or chemical abuse within 6 months
Pregnancy or lactation and all women must be willing to practice contraception through the study duration and for 3 months after discontinuing abatacept treatment.
- Sexually active women of childbearing potential must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized.
- Prior to study enrollment, women of childbearing potential (WOCBP) will be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.
- In addition, men enrolled on this study will be informed of the risks to any sexual partner of childbearing potential and counseled to practice an effective method of birth control.
- All WOCBP must have a negative urine pregnancy test within 7 days prior to first receiving the investigational product.
- If the pregnancy test is positive, the subject will be excluded from the study.
- In addition, all WOCBP will be instructed to contact the Investigator immediately if they suspect they might be pregnant (e.g., missed or late menstrual period) at any time during study participation and the Investigator will notify Bristol Myers Squibb (BMS) within 24 hours of becoming aware of a confirmed pregnancy in a subject participating in the study.
- Women must agree to practice adequate birth control for a minimum of 3 months post-treatment.
- Concomitant malignancies or previous malignancies within five years, with exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of cervix
- Atopic dermatitis, psoriasis, or autoimmune bullous skin disease (pemphigus, pemphigoid, etc)
- Significant cardiovascular disease (angina, arrhythmia, known coronary artery disease, cerebrovascular accident (CVA), transient ischemic attack (TIA), uncontrolled hypertension > 150/90)
- Significant pulmonary disease (asthma or chronic obstructive pulmonary disease (COPD) requiring current use of corticosteroids, history ever of severe asthma or status asthmatics)
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates an investigational drug or that may affect interpretation of the results or render patient at high risk from treatment complications
- Plans or need to receive live viral vaccination over course of the study (e.g., Flu-Mist)
- Inability to comply with study and follow-up procedures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Abatacept
4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 weeks, and 8 weeks.
|
4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events
Time Frame: baseline, 3 month and 6 months
|
Participants were monitored for adverse events (AEs) at each visit.
Cumulative AEs were tracked including specific AE, severity, and relationship on source documentation.
Special attention was given to infusion-related events and hypersensitivity reactions.
Assessment of Complete Blood Count (CBC) and Metabolic profile were also tracked.
|
baseline, 3 month and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Clinically Detectable Improvement
Time Frame: at each visit and at 3 months
|
Evaluations will occur at each visit after the first infusion.
At 3 months, response will be recorded and patients with improvement will be eligible to move into the steroid and/or antihistamine tapering portion of the study.
Improvement was determined by a reduction in the number of hives.
|
at each visit and at 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Clifton O. Bingham, M.D., Associate Professor of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2009
Primary Completion (Actual)
March 1, 2013
Study Completion (Actual)
March 1, 2013
Study Registration Dates
First Submitted
April 22, 2009
First Submitted That Met QC Criteria
April 22, 2009
First Posted (Estimate)
April 23, 2009
Study Record Updates
Last Update Posted (Estimate)
January 25, 2016
Last Update Submitted That Met QC Criteria
December 17, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Skin Diseases, Vascular
- Hypersensitivity
- Urticaria
- Chronic Urticaria
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Immune Checkpoint Inhibitors
- Abatacept
Other Study ID Numbers
- Tahoe-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urticaria
-
Marcus MaurerCompletedNon-autoreactive Chronic Spontaneous Urticaria | Autoimmune Chronic Spontaneous Urticaria | Autoreactive, Non-autoimmune Chronic Spontaneous UrticariaGermany
-
J. Uriach and CompanyTerminated
-
United BioPharmaCompleted
-
University Hospital, LilleRecruitingSpontaneous Urticaria, ChronicFrance
-
United BioPharmaNot yet recruiting
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedUrticaria ChronicUnited States
-
Novartis PharmaceuticalsCompletedCHRONIC SPONTANEOUS URTICARIAFrance
-
University Hospital Inselspital, BerneNovartis; University of Bern; Adverse Drug Reactions, Advice and Consulting ADR-ACCompletedChronic Idiopathic Urticaria | Chronic Urticaria | Chronic Spontaneous UrticariaSwitzerland
-
Novartis PharmaceuticalsTerminatedChronic Spontaneous Urticaria | Cold Urticaria | Cholinergic UrticariaGermany
-
United BioPharmaRecruiting
Clinical Trials on abatacept (Orencia ®)
-
Stuart Knechtle, M.D.TerminatedAutoimmune HepatitisUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedMultiple Sclerosis, Relapsing-RemittingUnited States, Canada
-
Momenta Pharmaceuticals, Inc.Mylan Inc.CompletedHealthy VolunteersUnited Kingdom
-
Bristol-Myers SquibbCompletedUlcerative ColitisUnited States, Australia, India, Korea, Republic of, Poland, Canada, France, Brazil, Mexico, Puerto Rico, Belgium, Switzerland, Italy, Netherlands, Germany, Ireland, South Africa, United Kingdom, Czech Republic
-
University Medical Center GroningenBristol-Myers SquibbCompletedSjögren's SyndromeNetherlands
-
Assistance Publique - Hôpitaux de ParisActive, not recruiting
-
University of California, Los AngelesBristol-Myers SquibbTerminated
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompleted
-
Marmara UniversityThe Scientific and Technological Research Council of TurkeyRecruitingLRBA Deficiency | CTLA4 HaploinsufficiencyTurkey
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisUnited States